Akero Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDAkero Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is moderate (RS Rating: 62), indicating performance broadly in line with the market. Earnings growth of 6% provides fundamental context to the price action. Investors should exercise caution due to high volatility (53% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $54.40 | +0.47% | ABOVE |
| 50 SMA | $53.06 | +3.00% | ABOVE |
| 100 SMA | $50.28 | +8.68% | ABOVE |
| 150 SMA | $50.20 | +8.86% | ABOVE |
| 200 SMA | $48.19 | +13.40% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is AKRO in an uptrend right now?
AKRO has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, AKRO is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is AKRO overbought or oversold?
AKRO's RSI (14) is 70. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is AKRO outperforming the market?
AKRO has a Relative Strength (RS) Rating of 62 out of 99. AKRO is performing about average compared to the market.
Where is AKRO in its 52-week range?
AKRO is trading at $54.65, which is 95% of its 52-week high ($57.35) and 87% above its 52-week low ($37.28).
How volatile is AKRO?
AKRO has a Beta of 0.35 and 52-week volatility of 53%. It's less volatile than the S&P 500 - generally more stable.